ESAR - European Surveillance of Antibiotic Resistance
All in-patients; infection and discipline known; 1999 and 2000
Therapy

Type of Infection: Respiratory Tract
  Total Type of therapy
missing Prophylaxis Treatment
N % N % N % N %
Substance 137 15.59 50 5.69 3 0.34 84 9.56
3rd gen. cephalosporins
aminopenicillin + -lact.inh. 128 14.56 45 5.12 11 1.25 72 8.19
quinolones 99 11.26 38 4.32 5 0.57 56 6.37
aminoglycosides 87 9.90 53 6.03 9 1.02 25 2.84
polypeptides 63 7.17 13 1.48 2 0.23 48 5.46
macrolides 57 6.48 17 1.93 - - 40 4.55
carbapenems 49 5.57 20 2.28 - - 29 3.30
2nd gen. cephalosporins 35 3.98 11 1.25 1 0.11 23 2.62
acylaminopenicillin + -lact.inh. 35 3.98 16 1.82 1 0.11 18 2.05
glycopeptide 33 3.75 17 1.93 1 0.11 15 1.71
aminopenicillin 31 3.53 16 1.82 3 0.34 12 1.37
methylpenicillin 30 3.41 5 0.57 - - 25 2.84
antifungals 23 2.62 9 1.02 3 0.34 11 1.25
penicillins 14 1.59 6 0.68 - - 8 0.91
1st gen. cephalosporins 12 1.37 5 0.57 - - 7 0.80
lincosamides 11 1.25 8 0.91 - - 3 0.34
sulfonamides 9 1.02 4 0.46 1 0.11 4 0.46
antituberculosis agents 6 0.68 - - - - 6 0.68
4th gen. cephalosporins 5 0.57 1 0.11 - - 4 0.46
acylaminopenicillin 5 0.57 3 0.34 2 0.23 - -
other 3 0.34 1 0.11 - - 2 0.23
tetracyclines 3 0.34 1 0.11 - - 2 0.23
cephalosporin 2 0.23 2 0.23 - - - -
misc. antivirals 1 0.11 - - - - 1 0.11
topical antiinfectives 1 0.11 - - - - 1 0.11
Total 879 100.00 341 38.79 42 4.78 496 56.43

ESBiC Study Center